CasNo.163222-33-1,Ezetimibe CAS 163222-33-1,(163222-33-1) Suppliers

1 Gram	FOB Price: USD 1000.0000

Min.Order :1 Gram
Purity: 99%
Payment Terms : T/T,,MoneyGram

Keywords

Ezetimibe CAS : 163222-33-1 163222-33-1

Quick Details

Appearance:white powder
Application:Animal Pharmaceuticals
PackAge:carton boc
ProductionCapacity:1000000|Kilogram|Month
Storage:cool and dry
Transportation:ship,fly

Superiority:

Hebei Mojin Biotechnology Co., Ltd,Our business covers more than 30 countries, most of the big customers come from Europe, America and other countries in the world, we can guarantee the quality and price. In recent decades, with the efforts of all employees, we have established many cooperative companies in shandong, henan, guangdong and other places. Our corporate purpose is based on the market, enhance the strength, take the road of scientific and environmental sustainable development, relying on the country. Technology r & d center, increase the investment in r & d, based on the domestic market, expand the international market, manufacturing quality products, sincere service to the society, into a modern, ecological, scientific and technological enterprise world.

Adenosine triphosphate can be used in the disease caused by tissue injury and activity reduction of ecto enzyme , including heart failure, carditis, miocardial infarction, cerebral arteriosclersis, coronary sclerosis, progressive muscular atrophy , cerebral hemorrhage , chronic hepatitis, cirrhosis of liver and hearing handicap, etc.

Details:

Product Detailed

Product Name	Ezetimibe
Minimum order quantity	100g
Price	Negotiable
Lead time	Within 24 hours upon receipt of payment
Delivery time	About 7 days
Packaging Details	Aluminum Foil Bags or Fiber Drum
Trade Terms	CIF, CFR, FOB
Payment Terms	T/T, L/C,

Ezetimibe is ananti-hyperlipidemic drug used for lowering the plasma cholesterol levels. It is indicated as an adjunctive therapy to diet for the reduction of high-level total-C, LDL-C, and ApoB in patients suffering primary (heterozygous familial and non-familial) hypercholesterolemia. It is also used in combination therapy with HMG-CoA reductase inhibitors.Ezetimibe does not inhibit the cholesterol synthesis in the liver, or increase bile acid excretion.It takes effect throughacting at the brush border of the small intestine and inhibiting the absorption of cholesterol, further leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of blood cholesterol.

Product picture